Literature DB >> 14965311

Efforts to understand the molecular basis of hypertension through drug:membrane interactions.

T Mavromoustakos1, P Zoumpoulakis, I Kyrikou, A Zoga, E Siapi, M Zervou, I Daliani, D Dimitriou, A Pitsas, C Kamoutsis, P Laggner.   

Abstract

Biological membranes play an essential role in the drug action. They constitute the first barrier for drugs to exert their biological action. AT1 antagonists are amphiphilic molecules and are hypothesized to act on AT1 receptor through incorporation (first step) and lateral diffusion through membrane bilayers (second step). Various biophysical methods along with Molecular Modelling were applied in order to explore the plausible two step proposed mechanism of action for this class of antihypertensive drugs.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14965311     DOI: 10.2174/1568026043451339

Source DB:  PubMed          Journal:  Curr Top Med Chem        ISSN: 1568-0266            Impact factor:   3.295


  4 in total

1.  Development of a CP 31P NMR broadline simulation methodology for studying the interactions of antihypertensive AT1 antagonist losartan with phospholipid bilayers.

Authors:  Charalambos Fotakis; Dionisios Christodouleas; Petros Chatzigeorgiou; Maria Zervou; Nikolas-Ploutarch Benetis; Kyriakos Viras; Thomas Mavromoustakos
Journal:  Biophys J       Date:  2009-03-18       Impact factor: 4.033

Review 2.  On the Rational Drug Design for Hypertension through NMR Spectroscopy.

Authors:  Eleni Chontzopoulou; Andreas G Tzakos; Thomas Mavromoustakos
Journal:  Molecules       Date:  2020-12-22       Impact factor: 4.411

Review 3.  Rational Design and Synthesis of AT1R Antagonists.

Authors:  Nikitas Georgiou; Vasileios K Gkalpinos; Spyridon D Katsakos; Stamatia Vassiliou; Andreas G Tzakos; Thomas Mavromoustakos
Journal:  Molecules       Date:  2021-05-14       Impact factor: 4.411

Review 4.  Ligands, their receptors and ... plasma membranes.

Authors:  G Vauquelin; A Packeu
Journal:  Mol Cell Endocrinol       Date:  2009-07-30       Impact factor: 4.102

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.